CYTOKINETICS, INCORPORATED Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 65 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-09-22: Reporting owner Malik Fady Ibraham; Form 4; Security Non-Qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-09-14: Reporting owner Blum Robert I; Form 4; Security Non-Qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-09-08: Reporting owner Malik Fady Ibraham; Form 4; Security Non-Qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-31: Reporting owner Callos Andrew; Form 4; Security Non-Qualified Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
CYTK insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-22 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 23,386 owned after | $7.80 exercise price | $67.59 | 2026-09-22 |
| 2026-09-14 | Blum Robert I Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 156,745 owned after | $10.60 exercise price | $72.45 | 2026-09-15 |
| 2026-09-08 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 26,886 owned after | $7.80 exercise price | $75.35 | 2026-09-08 |
| 2026-08-31 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 0 owned after | $23.26 exercise price | $70.91 | 2026-08-31 |
| 2026-08-31 | Blum Robert I Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 164,245 owned after | $10.60 exercise price | $70.91 | 2026-08-31 |
| 2026-08-18 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 30,386 owned after | $7.80 exercise price | $76.10 | 2026-08-18 |
| 2026-08-10 | Blum Robert I Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 171,745 owned after | $10.60 exercise price | $77.49 | 2026-08-10 |
| 2026-07-30 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,000 10,000 owned after | $23.26 exercise price | $80.42 | 2026-07-30 |
| 2026-07-27 | Blum Robert I Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 179,245 owned after | $10.60 exercise price | $80.62 | 2026-07-27 |
| 2026-07-21 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 33,886 owned after | $7.80 exercise price | $81.11 | 2026-07-23 |
| 2026-07-13 | Blum Robert I Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,490 186,745 owned after | $10.60 exercise price | $82.24 | 2026-07-14 |
| 2026-07-07 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 37,386 owned after | $7.80 exercise price | $85.56 | 2026-07-07 |
| 2026-07-01 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 24,000 owned after | $23.26 exercise price | $85.26 | 2026-07-02 |
| 2026-07-01 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,112 26,709 owned after | $48.51 exercise price | $85.26 | 2026-07-02 |
| 2026-06-29 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −188 8,828 owned after | $44.36 exercise price | $87.26 | 2026-06-29 |
| 2026-06-29 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −822 40,504 owned after | $44.36 exercise price | $87.26 | 2026-06-29 |
| 2026-06-29 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,113 52,304 owned after | $48.51 exercise price | $87.26 | 2026-06-29 |
| 2026-06-29 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −188 8,640 owned after | $44.36 exercise price | $87.26 | 2026-06-29 |
| 2026-06-29 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −823 39,681 owned after | $44.36 exercise price | $87.26 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,370 30,047 owned after | $48.51 exercise price | $81.20 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,307 32,019 owned after | $44.36 exercise price | $81.20 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,817 6,199 owned after | $44.36 exercise price | $81.20 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,113 28,934 owned after | $48.51 exercise price | $81.20 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −188 6,011 owned after | $44.36 exercise price | $81.20 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −822 31,197 owned after | $44.36 exercise price | $81.20 | 2026-06-29 |
| 2026-06-24 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,113 27,821 owned after | $48.51 exercise price | $81.20 | 2026-06-29 |
| 2026-06-23 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 40,886 owned after | $7.80 exercise price | $80.01 | 2026-06-23 |
| 2026-06-09 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 44,386 owned after | $7.80 exercise price | $68.45 | 2026-06-09 |
| 2026-06-01 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 39,000 owned after | $23.26 exercise price | $73.68 | 2026-06-01 |
| 2026-05-27 | Bhanji Muna Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | Daly James M Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | Harrington Robert Arthur Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | HENDERSON JOHN T Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | Kaye Edward M. MD Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | PARSHALL B LYNNE Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | Landry Robert E Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | WIERENGA WENDELL Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-27 | Wysenski Nancy Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,301 4,301 owned after | $77.15 exercise price | $77.15 | 2026-05-27 |
| 2026-05-19 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 47,886 owned after | $7.80 exercise price | $76.45 | 2026-05-20 |
| 2026-05-05 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 51,386 owned after | $7.80 exercise price | $77.09 | 2026-05-05 |
| 2026-05-05 | WIERENGA WENDELL Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,032 0 owned after | $12.40 exercise price | $77.09 | 2026-05-05 |
| 2026-05-05 | HENDERSON JOHN T Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 0 owned after | $7.61 exercise price | $77.09 | 2026-05-05 |
| 2026-05-05 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,333 13,070 owned after | $39.13 exercise price | $77.09 | 2026-05-05 |
| 2026-05-01 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,857 0 owned after | $37.63 exercise price | $63.35 | 2026-05-04 |
| 2026-04-30 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 54,000 owned after | $23.26 exercise price | $63.97 | 2026-04-30 |
| 2026-04-21 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 54,886 owned after | $7.80 exercise price | $65.80 | 2026-04-21 |
| 2026-04-07 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,500 58,386 owned after | $7.80 exercise price | $65.48 | 2026-04-08 |
| 2026-04-07 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,000 0 owned after | $10.60 exercise price | $65.48 | 2026-04-08 |
| 2026-03-15 | Blum Robert I Director, Officer (President & CEO) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,665 1,665 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Blum Robert I Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +111,864 111,864 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,665 1,665 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,480 29,480 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Hessekiel Jeffrey Officer (Chief Legal & Admin Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,325 8,325 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Hessekiel Jeffrey Officer (Chief Legal & Admin Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,820 22,820 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,665 1,665 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Lee Sung Officer (EVP, Chief Financial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,480 29,480 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,665 1,665 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-15 | Malik Fady Ibraham Officer (EVP Research & Development) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,527 39,527 owned after | $60.06 exercise price | $60.06 | 2026-03-17 |
| 2026-03-05 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,000 24,403 owned after | $39.13 exercise price | $62.19 | 2026-03-05 |
| 2026-03-05 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 69,000 owned after | $23.26 exercise price | $62.19 | 2026-03-05 |
| 2026-03-02 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −886 0 owned after | $37.63 exercise price | $61.43 | 2026-03-02 |
| 2026-02-05 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 84,000 owned after | $23.26 exercise price | $60.24 | 2026-02-05 |
| 2026-02-02 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −886 886 owned after | $37.63 exercise price | $65.16 | 2026-02-02 |
| 2026-01-05 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 99,000 owned after | $23.26 exercise price | $61.26 | 2026-01-05 |
| 2026-01-02 | Callos Andrew Officer (EVP, Chief Commercial Officer) | 4 | Incentive Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −885 1,772 owned after | $37.63 exercise price | $61.73 | 2026-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |